您要查找的是不是：
- Objective To evaluate the treatment of portal hypertensi on caused by tumor thrombi with percutaneous transhepatic portal vein stent implan tation under the US guidance. 目的探討通過(guò)超聲引導經(jīng)皮肝穿途徑向門(mén)脈內放置內支架治療癌栓引起的門(mén)靜脈高壓的效果。
- transhepatic portal vein catheterization 經(jīng)肝門(mén)靜脈插管(術(shù))
- transhepatic portal vein 經(jīng)肝門(mén)靜脈
- Strategy of Therapy for Portal Vein Spongiform in Children. 小兒門(mén)靜脈海綿樣變治療的思路。
- There were no tumor thrombi in the main portal vein. 門(mén)靜脈主干內未及癌栓。
- Of or relating to the portal vein or the portal system. 門(mén)靜脈門(mén)靜脈的，門(mén)靜脈系統的，與門(mén)靜脈系統有關(guān)的
- The color flow of the portal vein revealed no color,red,mosaic or filling defect. 結果 :pv內CDFI可顯示本色、紅色、混色或充盈缺損。
- MRI also suggested hepatic metastasis in 4 cases, portal vein invasion in 7 cases. MRI發(fā)現 4例肝轉移 ,7例門(mén)靜脈主干或分支受累。
- TPC(transhepatic portal catheterization) 經(jīng)肝門(mén)靜脈插管術(shù)
- transhepatic portal catheterization 經(jīng)肝門(mén)靜脈插管術(shù)
- Results The main portal vein appearance was accordant with 3D CE MRP and direct x-ray portography in all cases. 結果3D CE mrp和直接門(mén)靜脈造影顯示門(mén)靜脈主干的結果完全一致。
- transhepatic portal venous sampling 經(jīng)肝門(mén)靜脈取樣
- percutaneous transhepatic portal phlebography 經(jīng)皮經(jīng)肝門(mén)靜脈造影(術(shù))
- Preliminary survival observation on purcutaneous portal vein chronomodulated chemotherapy on treatment of liver cancer. 肝癌經(jīng)皮門(mén)靜脈時(shí)辰化療生存期的初步觀(guān)察。
- Samples of blood were collected from the radial artery, portal vein (PV) and hepatic vein (HV), in up to 120 minutes postreperfusion. 再灌注后120分鐘后從橈動(dòng)脈、門(mén)靜脈和肝靜脈采血液樣本。
- The portal vein injection of LUF in the rats is simple procedure and the results are reliable. 活體碘油門(mén)靜脈灌注方法簡(jiǎn)單易行,結果真實(shí)可靠;
- Compared with 30% PH,70% PH could obviously increase hepatocyte transgenic efficiency via rat portal vein. 與 30%25肝部分切除術(shù)相比 ,70%25切肝可顯著(zhù)提高大鼠肝細胞門(mén)靜脈途徑轉基因的效率
- DST,DSSL and DSBM can induce the specific tolerance by the way of portal vein infusion. 發(fā)現供者特異性輸血（DST）、供者特異性脾細胞（DSSL）和供者特異性骨髓細胞（DSBM）能誘導受體對供體移植物產(chǎn)生免疫耐受。
- Methods 108 3D DCE MRA and 10 2D DCE MRA were performed and compared in visulization of the right Portal vein branches. 方法門(mén)靜脈和肝臟靜脈系統行3DDCEMRA108次，二維（2D）DCEMRA10次。
- Index of bore of portal vein was lower in treatment group than that in control group after treatment (P < 0.01). 治療組治療后門(mén)靜脈內徑明顯小于對照組(P<0.;05)。
